Referencias bibliográficas

1. Amezcua L, McCauley JL. Race and ethnicity on MS presentation and disease course. Mult Scler. 2020 Apr;26(5):561-7. [Pubmed]
2. Rotstein D, Montalbán X. Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat Rev Neurol. 2019 May;15(5):287-300. [Pubmed]
3. Tintoré M, Rovira À, Río J, Otero-Romero S, Arrambide G, Tur C, et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain. 2015 Jul;138(Pt 7):1863-74. [Pubmed]
4. Renoux C, Vukusic S, Mikaeloff Y, Edan G, Clanet M, Dubois B, et al.;Adilt Neurology Departments KIDMUS Study Group. Natural history of multiple sclerosis with childhood onset. N Engl J Med. 2007;356(25):2603-13. [Pubmed]
5. Buscarinu MC, Reniè R, Morena E, Romano C, Bellucci G, Marrone A, et al. Disease Course and Safety-Efficacy of DMTS. Front Neurol. 2022 Mar 10;13:829331. [Pubmed]
6. Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, Daumer M, Ebers GC. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain. 2010 Jul;133(Pt 7):1914-29. [Pubmed]
7. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain. 2003 Apr;126(Pt 4):770-82. [Pubmed]
8. Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022 Jan 21;375(6578):296-301. [Pubmed]
9. Granziera C, Derfuss T, Kappos L. Time to Change the Current Clinical Classification of Multiple Sclerosis? JAMA Neurol. 2023 Feb 1;80(2):128-30. [Pubmed]
10. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13(3):227-31. [Pubmed]
11. Tremlett H, Yousefi M, Devonshire V, Rieckmann P, Zhao Y; UBC Neurologists. Impact of multiple sclerosis relapses on progression diminishes with time. Neurology. 2009 Nov 17;73(20):1616-23. [Pubmed]
12. Lublin FD, Häring DA, Ganjgahi H, Ocampo A, Hatami F, Čuklina J, et al. How patients with multiple sclerosis acquire disability. Brain. 2022 Sep 14;145(9):3147-61. [Pubmed]
13. Usta NC, Boz C, Terzi M. Early onset multiple sclerosis and the effect of disease onset age on neurological disability in multiple sclerosis. Clin Neurol Neurosurg. 2022 Nov 23;224:107528. Epub ahead of print. [Pubmed]
14. Tintoré M, Arrambide G, Otero-Romero S, Carbonell-Mirabent P, Río J, Tur C, et al. The long-term outcomes of CIS patients in the Barcelona inception cohort: Looking back to recognize aggressive MS. Mult Scler. 2020 Nov;26(13):1658-69. [Pubmed]
15. Río J, Rovira À, Tintoré M, Otero-Romero S, Comabella M, Vidal-Jordana Á, et al. Disability progression markers over 6-12 years in interferon-β-treated multiple sclerosis patients. Mult Scler. 2018 Mar;24(3):322-30. [Pubmed]
16. Sormani MP, Rio J, Tintorè M, Signori A, Li D, Cornelisse P, et al. Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler. 2013 Apr;19(5):605-12. [Pubmed]
17. Kalincik T, Manouchehrinia A, Sobisek L, Jokubaitis V, Spelman T, Horakova D, et al.; MSBase Study Group. Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. Brain. 2017 Sep 1;140(9):2426-43. [Pubmed]
18. Tur C, Carbonell-Mirabent P, Cobo-Calvo Á, Otero-Romero S, Arrambide G, Midaglia L, et al. Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis. JAMA Neurol. 2023 Feb 1;80(2):151-60. [Pubmed]
19. Cadavid D, Cohen JA, Freedman MS, Goldman MD, Hartung HP, Havrdova E, et al. The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. Mult Scler. 2017 Jan;23(1):94-105. [Pubmed]
20. Labiano-Fontcuberta A, Martínez-Ginés ML, Aladro Y, Ayuso L, Mitchell AJ, Puertas-Martín V, et al. A comparison study of cognitive deficits in radiologically and clinically isolated syndromes. Mult Scler. 2016 Feb;22(2):250-3. [Pubmed]
21. Deloire M, Ruet A, Hamel D, Bonnet M, Brochet B. Early cognitive impairment in multiple sclerosis predicts disability outcome several years later. Mult Scler. 2010 May;16(5):581-7. [Pubmed]
22. Kavaliunas A, Danylaite Karrenbauer V, Gyllensten H, Manouchehrinia A, Glaser A, Olsson T, et al. Cognitive function is a major determinant of income among multiple sclerosis patients in Sweden acting independently from physical disability. Mult Scler. 2019 Jan;25(1):104-12. [Pubmed]
23. Lavorgna L, Brigo F, Moccia M, Leocani L, Lanzillo R, Clerico M, et al. e-Health and multiple sclerosis: An update. Mult Scler. 2018 Nov;24(13):1657-64. [Pubmed]
24. Lavelle G, Norris M, Flemming J, Harper J, Bradley J, Johnston H, et al. Validity and Acceptability of Wearable Devices for Monitoring Step-Count and Activity Minutes Among People With Multiple Sclerosis. Front Rehabil Sci. 2022 Jan 11;2:737384. [Pubmed]
25. Van 't Hullenaar CAA, Coerver E, Kalkers NF, van Kempen Z, Koch M, Uitdehaag BMJ, et al. The use of multi-domain patient reported outcome measures for detecting clinical disease progression in multiple sclerosis. Mult Scler Relat Disord. 2021 Oct;55:103165. [Pubmed]
26. Golan D, Sagiv S, Glass-Marmor L, Miller A. Mobile-phone-based e-diary derived patient reported outcomes: Association with clinical disease activity, psychological status and quality of life of patients with multiple sclerosis. PLoS One. 2021 May 5;16(5):e0250647. [Pubmed]